Corona Remedies Builds Momentum for Its Rs.655-Crore IPO With Strong Myoril Push

Corona Remedies Turns Myoril Acquisition Into a High-Growth Engine Ahead of Its ₹655-Crore IPO

In the months leading up to its ₹655-crore initial public offering (IPO), Corona Remedies Limited has managed to create a compelling growth narrative centered around its successful turnaround of the Myoril pain management brand. Acquired from Sanofi in FY23, the brand has transitioned from a modest portfolio addition into a fast-expanding engine that has significantly strengthened the company’s presence in the pain management segment. This transformation has not only delivered strong financial results but has also emerged as a key proof of execution for investors evaluating the company’s long-term prospects before the IPO.

Myoril’s Sales Nearly Triple as Margins Expand Sharply Under Corona Remedies’ Execution Strategy

According to Nirav Mehta, Promoter, MD & CEO, Myoril has seen remarkable growth since its acquisition. What was once a ₹27–28 crore brand has now been scaled to a targeted ₹90-crore-plus business within just two financial years. Mehta highlighted that Myoril did not merely add incremental revenue but evolved into a strategically relevant brand that strengthened Corona Remedies’ positioning in the rapidly growing pain management category.

Alongside sales expansion, the brand has delivered an 800-basis-point improvement in gross margins, reflecting stronger operational control, optimized manufacturing, and more efficient marketing through the company’s field force. Mehta stated that Myoril was a “perfect strategic fit” that allowed Corona Remedies to capitalise on its existing therapy strength while accelerating growth in a segment that continues to expand due to rising lifestyle-related disorders and increased healthcare awareness.

Also Read : Chemical Firm Finalises Record Date for Bonus and Stock Split to Reward Shareholders

Corona Remedies Continues to Build a Strong Pharma Franchise With Strategic Acquisitions

Corona Remedies has built a reputation as an India-focused branded formulations company with presence across women’s healthcare, cardio-diabeto, pain management, urology, and other therapeutic areas. Over the past decade, the company has adopted a measured but focused approach to acquisitions, ensuring that each acquired brand is integrated with precision and positioned for scale.

Mehta emphasized that past acquisitions from multinational giants such as Sanofi, Abbott and Glaxo have added significant value and helped diversify the company’s therapy portfolio. He added that future acquisitions will remain selective, with the company targeting only those brands where it can “do justice” through effective marketing, improved availability, and wide distribution coverage.

₹655-Crore IPO Structured as a Pure Offer for Sale to Enable Partial Stake Monetisation

The upcoming IPO of ₹655 crore will be a pure Offer for Sale (OFS) without any new shares being issued. This structure signals the company’s strong financial position and its confidence in sustaining growth without the need for fresh capital.
Mehta explained that the IPO will involve a 10.09% divestment, including a 3.5% stake sale by the promoter family and a 6.59% sale by private equity investor ChrysCapital, which currently holds 27.5% in the company. ChrysCapital, he noted, remains deeply committed to Corona Remedies and intends to pursue a phased exit in the coming years rather than an immediate withdrawal.

Strong Cash Flows Allow Corona Remedies to Pursue Growth Without External Funding

A key highlight supporting investor interest is Corona Remedies’ strong internal cash generation. Mehta noted that the company consistently generates robust operating cash flows, giving it the flexibility to fund expansions, new product launches, and selective acquisitions without relying on external capital. This strong cash position is a major reason why the IPO does not include a fresh issue, illustrating the company’s ability to grow organically and inorganically through internal resources.

Operating Margins Strengthen to Over 20% as Scale, Reach and Focused Execution Drive Profitability

Corona Remedies’ margin performance has also shown significant improvement. Operating margins have expanded from around 15% in FY23 to 20–21% in recent quarters, driven by rapid volume growth, broader geographic penetration, and improved efficiencies in manufacturing and marketing.
Mehta said that this structural improvement reflects the success of the company’s strategy of scaling high-potential products, expanding its field force, and strengthening distribution across India. The combination of scale benefits, strong brand contributions, and disciplined execution has positioned the company among the fastest-growing pharma companies by volume within India’s top 30 firms.

Company Bullish on Market Share Gains Across Core Therapies

With a diversified portfolio and a strong track record in both organic growth and acquisition-led expansion, Corona Remedies remains optimistic about increasing its market share in core therapeutic areas. The company continues to see strong momentum in women’s healthcare and cardio-diabetes therapies, both of which are considered high-growth categories within India’s pharmaceutical market.

IPO Expected to Mark a Key Milestone as Corona Remedies Enters a New Phase of Expansion

As Corona Remedies approaches its ₹655-crore IPO, investor interest is rising, driven by the company’s strong financial metrics, brand-building capabilities, and successful execution in scaling acquired brands such as Myoril. With improved margins, wider geographic reach, and strong internal cash flows, the company is well-positioned to continue its growth trajectory post-listing.

The Myoril success story, in particular, serves as a powerful indicator of the management’s ability to transform acquisitions into long-term value generators—an attractive proposition for investors looking at the company’s future potential.

• Nifty 50
• Bank Nifty
• Sensex